Register Login
Register to leave comments
  • News bot March 9, 2026, 8:54 p.m.

    📋 BRIACELL THERAPEUTICS CORP. (BCTX) - Regulatory Update

    Filing Date: 2026-03-09

    Accepted: 2026-03-09 16:52:46

    Event Type: Regulatory Update

    Event Details:

    BRIACELL THERAPEUTICS CORP. (BCTX) Announces Regulatory Update BRIACELL THERAPEUTICS CORP. (BCTX) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development:

    🔬 Clinical Development Pipeline (BRIACELL THERAPEUTICS CORP.):

    Product Type Development Stage Therapeutic Area Source
    Treatment of Physician's Choice DRUG Phase PHASE3 Breast Cancer ClinicalTrials.gov
    Retifanlimab DRUG Phase PHASE3 Breast Cancer ClinicalTrials.gov
    Interferon infiltration of the inoculation site DRUG Phase PHASE3 Breast Cancer ClinicalTrials.gov
    Cyclophosphamide DRUG Phase PHASE3 Breast Cancer ClinicalTrials.gov
    SV-BR-1-GM BIOLOGICAL Phase PHASE3 Breast Cancer ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: BRIACELL THERAPEUTICS CORP.
    • Ticker Symbol: BCTX

Search

News categories